LIXELLE®, β2-microglobulin adsorption column for dialysis-related amyloidosis patients
Treatment with the LIXELLE® system is indicated for dialysis-related amyloidosis patients not responding to conventional medications. The LIXELLE® column is designed to adsorb β2-microglobulin. It’s filled with cellulose porous microspheres coated by hexadecyl hydrophobic group as a ligand (Figure 1).
Total proteins, albumin and immunoglobulins levels and complement factors are not affected by this adsorption mechanism.  Clinical studies demonstrated that therapy with LIXELLE® reduced bone cysts and improved clinical amyloidosis correlated symptoms.
LIXELLE® is used in-series with a dialyzer. The extracorporeal circuit for using LIXELLE® is schematically demonstrated in the figure shown below.
Flow scheme – LIXELLE®
LIXELLE® is available in two sizes:
|LIXELLE® S-15||LIXELLE® S-35|
 IFU LIXELLE
 Tani N, Kidney and Dialysis. Supplement 1995; 54-57
 Nakatani et al Japanese Artificial Organ 1998; 27:571-577
 Furuyoshi S. et al Jpn J Apheresis 12(3):152-153
 Kuragano T et al, Blood Purif. 2011; 32:317-322
 Yamamoto Y et al, Ther Apher & Dial 2011; 15(5):466-474